Dermata Therapeutics (NASDAQ:DRMA) Upgraded at Wall Street Zen
by Teresa Graham · The Cerbat GemWall Street Zen upgraded shares of Dermata Therapeutics (NASDAQ:DRMA – Free Report) to a sell rating in a report issued on Saturday.
Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Dermata Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Research Report on Dermata Therapeutics
Dermata Therapeutics Trading Down 10.2%
NASDAQ DRMA opened at $2.02 on Friday. Dermata Therapeutics has a 1 year low of $1.58 and a 1 year high of $23.70. The company has a fifty day simple moving average of $2.44 and a 200 day simple moving average of $4.08. The company has a market cap of $5.74 million, a P/E ratio of -0.26 and a beta of 0.54.
Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.59) by ($0.06).
Dermata Therapeutics Company Profile
Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.
At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.